• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022
• UB-312 Phase 1 Part B Trial for Parkinson’s Completes Last Patient Last Dose, and Remains on Track to Complete an End-of-Treatment Analysis in the Second Half of 2022